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Non–small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large
proportion of all cancer-related deaths. Current treatment options are inadequate, reflecting a substantial
unmet clinical need. Increasing knowledge regarding the mechanisms and genetic aberrations underlying
tumor development and growth has heralded a new era of therapy in oncology, moving away from indis-
criminate cytotoxic chemotherapy toward more finely focused, targeted medicine. The development of
small-molecule drugs and monoclonal antibodies directed toward specific components of dysfunctional
molecular or immune pathways, and mutated genes specific to particular cancer types, is leading the field
to more personalized and less toxic treatment options, many of which have demonstrated greater efficacy
and survival benefits than their chemotherapeutic counterparts. Particularly successful examples are
agents that interfere with the programmed death 1 (PD-1) pathway, which many tumors can hijack to
avoid immune surveillance and editing. Pembrolizumab, a monoclonal antibody directed at PD-1 that
blocks the engagement between PD-1 and its ligands, has been explored as a treatment for solid tumors,
and demonstrated survival benefits in several studies. The use of PD-1 inhibitors such as nivolumab and
pembrolizumab in advanced cancers is widespread, and pembrolizumab is available in more than 60
countries for at least one of the following: advanced melanoma, PD-L1–expressing NSCLC, head and neck
squamous cell carcinoma, and adult and pediatric patients with refractory classical Hodgkin’s lymphoma.
This work provides a brief overview of the role of pembrolizumab in the treatment of advanced (recur-
rent/metastatic) NSCLC.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lung cancer is a major worldwide health problem, with an esti-
mated 1.8 million new cases globally in 2012, representing 12.9%
of all new cancer cases [1]. There are two main subsets of lung can-
cer: small cell lung cancer (SCLC) and non–SCLC (NSCLC); NSCLC, as
a group of different cancers, comprises approximately 85% of all
lung cancers, with an estimated 1.55 million new cases globally
in 2012 [1,2]. Lung cancer was responsible for the highest number
of cancer deaths worldwide in 2012, estimated at 1.59 million,
which represents 19.4% of all cancer deaths. That figure is more
than twice the number attributable to the second most common
cause of cancer deaths—liver cancer (745,000 deaths) [1]. The high-
est number of cancer deaths for both sexes in the United States and
Europe is attributed to lung cancer, and in Europe, lung cancer
accounts for more than the total number of deaths from colorectaland breast cancer combined [1]. These statistics highlight the sub-
stantial global burden associated with lung cancer, and NSCLC in
particular, and emphasize the need for novel treatment
approaches.Current treatment recommendations
First-line therapy
Traditionally, the standard first-line treatment for NSCLC has
been platinum-based combination doublet chemotherapy regi-
mens, and although none was found to be superior to the other
[3], frequently used first-line treatments in the United States are
gemcitabine + cisplatin for squamous cell carcinoma and cisplatin
(or carboplatin) + pemetrexed or carboplatin + paclitaxel (+beva-
cizumab) for non-squamous NSCLC [4]. Cisplatin + pemetrexed is
the preferred treatment recommended in the European Society
for Medical Oncology (ESMO) guidelines for the first-line treatment
of non-squamous NSCLC patients younger than 70 years of age
with an ECOG performance status of 0–1 [5]. Bevacizumab should
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patients with advanced NSCLC and Eastern Cooperative Oncology
Group performance status (ECOG PS) score of 0–1 [5]. If platinum
therapy is contraindicated, then non-platinum-based chemother-
apy with third-generation agents such as gemcitabine, vinorelbine,
and taxanes can be considered [4,5]. Maintenance chemotherapy
with pemetrexed is recommended for patients with an ECOG PS
score of 0–1 and partial response or stable disease after first-line
therapy [5]. Phase III clinical studies examining the different regi-
mens and duration of platinum-based combination therapies
demonstrated dismal median progression-free survival (PFS) and
overall survival (OS) times of approximately 4–8 and 6–16 months,
respectively [3,6], with 1-year OS rates as low as 30–40%. There-
fore, therapies that improve PFS and OS are warranted.
Second-line therapy
Treatment options for patients who experience relapse or
become resistant to first-line therapies include chemotherapeutics
such as docetaxel and pemetrexed, which are approved as second-
line therapies for the treatment of locally advanced or metastatic
NSCLC [7–9]. In Europe, pemetrexed is generally used as first-line
therapy for non-squamous NSCLC [5]; therefore, docetaxel is the
only approved chemotherapy option for patients who experience
disease progression on pemetrexed. Although docetaxel is associ-
ated with response rates of around 10% and 1-year survival rates
of 30–40%, it is associated with serious toxicity [10–12]. Lack of
options for second-line therapy in patients who do not respond
to or who experience progression on first-line therapy has been a
concern for many clinicians.Targeted therapy in NSCLC
Over the past decade, several targeted therapies for NSCLC have
been developed, almost exclusively targeting adenocarcinoma,
characterized by mutations of the gene encoding epidermal growth
factor receptor (EGFR) and rearrangement of those encoding
anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1)
[13]. Activating EGFR mutations occur in 10–60% of patients with
NSCLC, with higher frequencies occurring in Asian populations,
never smokers and among females compared with males [14,15],
and ALK translocations occur in 2–20% of patients and result in
increased cellular proliferation and thereby tumorigenesis [16–
18]. The benefit of targeted therapies in patients with these two
genetic aberrations is such that biomarker testing is now recom-
mended as part of the pathology workup for all patients with
NSCLC [4,5].
As of 2016, EGFR inhibitors recommended for the treatment of
NSCLC include erlotinib, afatinib, or gefitinib [4,5]. However, a
common limitation of EGFR tyrosine kinase inhibitors (TKIs) is
acquired resistance after a median of 9–13 months [19], highlight-
ing the need for the development of additional novel targeted drug
treatments such as osimertinib against NSCLC with the acquired
EGFR mutation T790M [20]. The T790M mutation accounts for
the TKI resistance in about 60% of relapsing patients [21].
Crizotinib is indicated as a first-line treatment in both Europe
and the United States for NSCLC in patients with ALK (or ROS1)
translocation identified before first-line chemotherapy
[4,5,22,23]. As with EGFR-TKIs, patients ultimately develop resis-
tance to ALK inhibitors, usually within 1–2 years [17]. Recent
approval of ceritinib and alectinib for patients who experience dis-
ease progression with or who are intolerant of crizotinib therapy
and development of additional ALK inhibitors are promising devel-
opments [24–28]. Of note, alectinib was recently shown to repre-sent a new standard of care frontline, with significantly better
PFS outcome and central nervous system control as compared with
crizotinib [29]. Many other driver oncogenes are being evaluated
as treatment targets in NSCLC, including MET, HER2, BRAF, and
KRAS mutations, as well as RET and NTRK rearrangements [30].The PD-1 pathway and NSCLC
Failure to mount an effective antitumor immune response is a
characteristic of cancer growth and progression [31]. PD-1 is highly
expressed on the surface of activated T cells in response to inflam-
mation or infection, acting as an ‘‘immune checkpoint.” Tumor
cells can evade the immune response through the upregulated
expression of PD-L1.
When bound to its ligand PD-L1, the complex PD-1/PD-L1 acts
to inhibit the immune response by inhibiting the cytotoxic T-cell
response (Fig. 1) [31–33]. Tumor cells can utilize this pathway to
promote immunosuppression, thereby evading antitumor activity.
PD-1 or PD-L1 inhibitors disrupt this inhibitory T-cell signaling,
thus reactivating the antitumor activity of specific cytotoxic T cells
[31,32]. Up to 68% of NSCLC tumors have been shown to express
PD-L1 [34,35]. Recently, there has been enormous activity in inves-
tigating targeting of the PD-1 pathway using monoclonal antibod-
ies raised against not only the PD-1 protein, but also its ligand PD-
L1, as a treatment for several distinct advanced malignancy,
including NSCLC (Fig. 2) [34].
The immune checkpoint inhibitors nivolumab, pembrolizumab
(which target the PD-1 pathway), and atezolizumab (which targets
PD-L1) have been approved by regulatory authorities [36–41]. In
the National Comprehensive Cancer Network (NCCN) and Euro-
pean Society for Medical Oncology NSCLC treatment guidelines,
anti–PD-1 inhibitors are currently recommended for subsequent
treatment of patients with disease progression on or after first-
line chemotherapy [4,5], and in the NCCN guidelines as a first-
line therapy in strongly PD-L1–expressing tumors with no EGFR
or ALK genomic aberrations [4]. Table 1 summarizes the studies
that supported regulatory approval for these agents. The pivotal
studies resulting in the US Food and Drug Administration (FDA)/
European Medicines Agency (EMA) approval of pembrolizumab
for NSCLC and ongoing studies in patients with lung cancer will
be discussed.Pembrolizumab
Pembrolizumab is a humanized immunoglobulin (Ig) G4 kappa
PD-1 monoclonal antibody that first received FDA approval in the
United States in 2014, then in Europe by the EMA in 2015, for
the treatment of treatment-refractory melanoma [36,42,43]. Pem-
brolizumab was granted FDA breakthrough therapy designation for
the treatment of advanced NSCLC in 2014, FDA approval in 2015,
and EMA approval in 2016 for the treatment of metastatic NSCLC
with PD-L1 expression and progression on or after platinum-
based chemotherapy (or FDA-approved EGFR- or ALK-targeting
therapy, where applicable) [36,44]. Pembrolizumab is recom-
mended in the National Comprehensive Cancer Network and Euro-
pean Society for Medical Oncology guidelines for the treatment of
patients with advanced NSCLC with PD-L1 expression (level of rec-
ommendation category 1) [4,5]. Recently, it was approved by the
FDA, EMA, and Japanese Pharmaceuticals and Medical Devices
Agency (PMDA) for the treatment of patients with metastatic
NSCLC and high PD-L1 expression [tumor proportion score (TPS)
50%] with no EGFR or ALK genomic tumor aberrations and no
prior chemotherapy [40,41,45].
Fig. 1. The function of PD-1 in T-cell signaling [33]. APC = antigen-presenting cell; IL-2 = interleukin 2; ITIM = immunoreceptor tyrosine-based inhibitory motif; ITSM =
immunoreceptor tyrosine-based switch motif; MHC = major histocompatibility complex; PD-1 = programmed death 1; PD-L1/L2 = programmed death ligand 1/2; PI3K =
phosphoinositide 3-kinase; SHP-2 = cytoplasmic SH2 domain containing protein tyrosine phosphatase; TCR = T-cell receptor. Republished with permission of American
Society of Hematology from Armand P. Blood 2015;125:3393–400. Permission conveyed through Copyright Clearance Center, Inc.
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The phase I KEYNOTE-001 (ClinicalTrials.gov, NCT01295827)
study was an international clinical trial that investigated the safety
and antitumor efficacy of pembrolizumab in patients with solid
tumors (including advanced NSCLC), in previously treated and
untreated patients. Patients received pembrolizumab via intra-
venous administration at 2 mg or 10 mg/kg every 3 weeks or 10
mg/kg every 2 weeks. The study endpoints were safety, side effect
profile, and efficacy (objective response rate [ORR], OS, PFS, dura-
tion of response [DOR], and disease progression) [31]. Observation
of an association between PD-L1 expression and pembrolizumab
efficacy [46] led to a protocol amendment of an additional primary
endpoint evaluating efficacy in NSCLC patients with a high level of
PD-L1 expression [31]; the findings related to PD-L1 expression
will be discussed separately herein.
Pembrolizumab demonstrated a good safety profile with
minimal toxicity in patients with NSCLC. Grade  3 adverse
events were observed in 10% of patients. Treatment-related
adverse events (TRAEs) were reported in 71% of patients(70.9%), with no differences observed between dosage or dos-
ing schedule [31].
The tolerable safety profile of pembrolizumab was coupled with
promising efficacy. The ORR for the overall population with NSCLC,
which included both treatment-experienced (n = 394) and
treatment-naive patients (n = 101) was 19% (95% confidence inter-
val [CI] 16–23), with stable disease in 22% with no differences
between dosage and dosing schedules for all patients. The ORR
for the treatment-experienced (83% had received  2 prior lines
of therapy) and naive patients was 18% (95% CI 14–22) and 25%
(95% CI 17–34), respectively. Median PFS and OS were 3.7 months
(95% CI 2.9–4.1) and 12.0 months (95% CI 9.3–14.7), respectively,
for the entire cohort [31]. In an updated survival analysis after a
median follow-up of 22 months, median OS was 22.1 months
(95% CI 16.8–27.2) in treatment-naive patients and 10.6 months
(95% CI 8.6–13.3) in previously treated patients [47].
The safety and efficacy findings of this phase I study prompted
the initiation of additional phase I–III studies to further investigate
the use of pembrolizumab as a single agent and in combination
with other therapeutics in patients with NSCLC (Table 2), in partic-
Fig. 2. Mechanism of action of the anti–PD-1 antibody pembrolizumab. MHC = major histocompatibility complex; PD-1 = programmed death 1; PD-L1 = programmed death
ligand 1.
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NCT01905657), the phase III KEYNOTE-024 trial (ClinicalTrials.gov,
NCT02142738), and the phase I/II KEYNOTE-021 trial (ClinicalTri-
als.gov, NCT02039674) [48].
KEYNOTE-010
The KEYNOTE-010 study (NCT01905657) was a randomized,
open-label, phase II and III clinical trial comparing the safety and
efficacy of pembrolizumab with docetaxel in patients with NSCLC
whose tumors express PD-L1. Patients were assigned to one of
three treatment groups: pembrolizumab at 2 mg/kg (n = 345), 10
mg/kg (n = 346) every 3 weeks, or docetaxel 75 mg/m2 (n = 343)
every 3 weeks. The primary endpoints were OS and PFS in all
patients and in the subset of patients whose tumors expressed
higher levels of PD-L1; the relevance of PD-L1 expression and effi-
cacy will be discussed in the ‘‘Role of PD-L1 as a predictivebiomarker” section. Secondary endpoints included safety, response
rate, and DOR [49].
Pembrolizumab demonstrated an improved OS benefit at both
tested doses in the total population compared with docetaxel.
Median OS was 10.4 months (95% CI 9.4–11.9), 12.7 months (95%
CI 10.0–17.3), and 8.5 months (95% CI 7.5–9.8) in the pem-
brolizumab 2-mg/kg, 10-mg/kg, and docetaxel treatment groups,
respectively [49]. The hazard ratios (HRs) of pembrolizumab 2
mg/kg and 10 mg/kg versus docetaxel were 0.71 (95% CI 0.58–
0.88; P = .0008) and 0.61 (95% CI 0.49–0.75; P < .0001), respec-
tively. OS was similar regardless of pembrolizumab dose (HR
1.17; 95% CI 0.94–1.45) [49]. Differences in PFS were not statisti-
cally significant between either of the pembrolizumab doses and
docetaxel (prespecified P value for significance; P < .001). The HR
of pembrolizumab 2 mg/kg and 10 mg/kg versus docetaxel was
0.88 (95% CI 0.74–1.05; P = .07) and 0.79 (95% CI 0.66–0.94;
P = .004); median PFS was 3.9 months (95% CI 3.1–4.1), 4.0 months
Table 1
Key clinical trials of PD-1 and PD-L1 inhibitors in patients with NSCLC.
Clinical trial Treatment and comparator
(if any)
Purposes N Efficacy results
Nivolumab
CheckMate017
NCT01642004
phase III [79]
Nivolumab vs docetaxel Compare OS of nivolumab and
docetaxel in patients with
squamous NSCLC after failure of
prior platinum-based therapy
272  Median OS 9.2 months with nivolumab vs 6.0 months with doc-
etaxel; HR 0.59; 95% CI 0.44–0.79; P < 0.001
 OS at 1 year was 42% vs 24%
 ORR was 20% vs 9% (P = .008)
 Median PFS was 3.5 months vs 2.8 months; HR 0.62; 95% CI
0.47–0.81; P < 0.001
 PD-1 expression was not prognostic or predictive
CheckMate057
NCT01673867
phase III [76]
Nivolumab vs docetaxel Compare OS of nivolumab and
docetaxel in patients with non-
squamous NSCLC after failure of
platinum-based therapy
292  Median OS was 12.2 months in nivolumab group vs 9.4 months
in the docetaxel group; HR 0.73; 96% CI 0.59–0.89; P = .002
 OS rate at 1 year was 51% vs 39%
 Response rate was 19% vs 12% (P = .02)
 PFS was 2.3 months vs 4.2 months, but the rate of PFS at 1 year
was greater with nivolumab (19%) than with docetaxel (8%)
CheckMate026
NCT02041533
phase III [81]
Nivolumab vs chemotherapy Compare the PFS of nivolumab
and investigator’s choice of
chemotherapy as first-line
treatment in patients with PD-
L1 + NSCLC
541  In patients with  5% PD-L1 expression (n = 423), median PFS
was 4.2 months with nivolumab and 5.9 months with
chemotherapy; HR 1.15; 95% CI 0.91–1.45; P = .25
Pembrolizumab
KEYNOTE-001
NCT01295827
phase I [31]
Pembrolizumab Assess safety and efficacy of
pembrolizumab in patients with
advanced NSCLC
495  ORR 19.4%
 Median PFS was 3.7 months
 Median PFS in patients with 50% TPS was 6.3 months
 Median OS was 12.0 months
KEYNOTE-010
NCT01905657
phase II/III [49]
Pembrolizumab vs docetaxel Compare the safety and efficacy
of pembrolizumab and docetaxel
in patients with previously
treated NSCLC
1034  Median OS was 10.4 months on 2 mg/kg pembrolizumab and
12.7 months with pembrolizumab 10 mg/kg vs 8.5 months with
docetaxel
 OS was significantly longer with pembrolizumab 2 mg/kg than
with docetaxel (HR 0.71; 95% CI 0.58–0.88; P = .0008) and 10
mg/kg (HR 0.61; 95% CI 0.49–0.75; P < .0001)
 In patients with TPS  50%, OS was significantly longer with
pembrolizumab than with docetaxel in both the 2 mg/kg dose
(median 14.9 months vs 8.2 months; HR 0.54; 95% CI 0.38–
0.77; P = .0002) and the 10 mg/kg dose (17.3 months vs 8.2
months; HR 0.50; CI 0.36–0.70; P < .0001)
KEYNOTE 021
cohort G [53]
NCT02039674
Pembrolizumab in
combination with
chemotherapy or
immunotherapy
Determine safety, tolerability,
and efficacy of pembrolizumab
in combination with
chemotherapy or
immunotherapy
123  Objective response was reported in 18 of 63 patients in the
chemotherapy group and 33 of 60 in pembrolizumab +
chemotherapy arm; incidence of grade 3 or worse TRAE was
similar between groups
KEYNOTE-024
NCT02142738
phase III [51]
Pembrolizumab vs platinum-
based chemotherapies
Compare the efficacy and safety
of pembrolizumab and
platinum-based chemotherapies
as first-line treatment in patients
with PD-L1–expressing (TPS 
50%) NSCLC
305  Median PFS was 10.3 months (95% CI 6.7–NR) on pem-
brolizumab 200 mg Q3W vs 6.0 months (95% CI 4.2–6.2) for
chemotherapy; HR 0.50; 95% CI 0.37–0.68; P < .001
 6-month OS was 80.2% vs 72.4%; HR 0.60, 95% CI 0.41–0.89; P =
0.005
 ORR = 44.8% vs 27.8%
Atezolizumab
POPLAR
NCT01903993
phase II[35]
Atezolizumab vs docetaxel Evaluate efficacy and safety of
atezolizumab and docetaxel in
patients with NSCLC after failure
of platinum-containing
chemotherapy
287  ORR was the same with atezolizumab and docetaxel: n = 21
(15%)
 Median PFS was 2.7 months for atezolizumab, 3.0 months for
docetaxel
 Median OS was 12.6 months vs 9.7 months (P = .04)
 OS was significantly improved for all patients with any level of
PD-L1 expression (in tumor cells or tumor-infiltrating immune
cells) who received atezolizumab vs docetaxel
BIRCH
NCT02031458
phase II [90]
Atezolizumab Evaluate efficacy and safety of
atezolizumab in patients with
PD-L1–positive, locally advanced
or metastatic NSCLC in first-,
second- or later line (C1, C2, C3)
667  ORRs in the C1, C2, and C3 subgroups ranged from 17% to 27%
 6-month PFS rates in C1, C2, and C3 were 29–48%
 6-month OS rates in C1, C2, and C3 were 71–82%
OAK
NCT02008227
phase III [91]
Atezolizumab vs docetaxel Evaluate efficacy and safety of
atezolizumab and docetaxel in
patients with NSCLC after failure
of platinum-containing
chemotherapy
1225  Primary efficacy analysis conducted on 850 of 1225 enrolled
 OS: HR for atezolizumab vs docetaxel was 0.73; P = .0003
 Median PFS was 2.8 months vs 4.0 months
 ORR = 13.6% vs 13.4%
 OS for patients with PD-L1 expression of TC 1/2/3 or IC 1/2/3 was
HR 0.74; P = .0102 for atezolizumab vs docetaxel
 OS was improved regardless of PD-L1 expression (including no
expression)
Abbreviations: CI = confidence interval; CR = complete response; HR = hazard ratio; IC0 = no PD-L1 expression in tumor-infiltrating immune cells; NR = not reported; NSCLC
= non–small cell lung cancer; ORR = objective response rate; OS = overall survival; PD-1 = programmed death 1; PD-L1 = programmed death ligand 1; PFS = progression-free
survival; PR = partial response; TC0 = no PD-L1 expression in tumor cells; TPS = tumor proportion score; TRAE = treatment-related adverse event.
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Table 2
Ongoing key trials of pembrolizumab in NSCLC.
Clinical trial Purposes N Endpoints Expected
primary
completion
date
Estimated
study
completion
KEYNOTE-021a
NCT02039674
phase I/II
Determine safety, tolerability, and efficacy of pembrolizumab in combination
with chemotherapy or immunotherapy in patients with unresectable or
metastatic NSCLC
308 ORR, OS, PFS, and DOR November 2016 October
2019
KEYNOTE-042
NCT02220894
phase III
Investigate efficacy of agent pembrolizumab for up to 35 treatments vs
standard-of-care platinum-based chemotherapy in patients with PD-L1
expressing NSCLC
1240 OS and PFS February 2018 February
2018
KEYNOTE-189
NCT02578680
phase III
Investigate efficacy of pembrolizumab in combination with platinum and
pemetrexed vs platinum and pemetrexed therapy as first-line therapy in
patients with non-squamous NSCLC
570 PFS, ORR, OS, and PFS
by immune-related
RECIST
September
2017
March 2019
KEYNOTE-407
NCT02775435
phase III
Investigate efficacy of pembrolizumab in combination with carboplatin and
paclitaxel/nab-paclitaxel vs carboplatin and paclitaxel/nab-paclitaxel therapy
as first-line therapy in patients with squamous NSCLC
560 PFS, OS, and ORR March 2018 August 2019
Abbreviations: DOR = duration of response; NSCLC = non–small cell lung cancer; ORR = objective response rate; OS = overall survival; PD-L1 = programmed death ligand 1;
PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors; TPS = tumor proportion score.
Endpoints in boldface are primary endpoints.
a Pembrolizumab investigated as a combination drug.
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docetaxel groups, respectively [49].
Pembrolizumab had a better safety profile than docetaxel, with
fewer high-grade TRAEs, and the profile of the pembrolizumab
treatment groups was as expected from the KEYNOTE-001 study
[49]. TRAEs of grade  3 were reported in 43 of 339 patients
(13%) and 55 of 343 patients (16%) in the pembrolizumab 2-mg/
kg and 10-mg/kg groups, respectively, in comparison with 109 of
309 patients (35%) in the docetaxel group. TRAEs leading to study
discontinuation occurred in 4%, 5%, and 10% of patients in the pem-
brolizumab 2-mg/kg, 10-mg/kg, and docetaxel groups, respec-
tively. It was concluded that pembrolizumab 2 mg/kg and 10 mg/
kg administered every 3 weeks conferred an OS benefit in all
patients [49].
KEYNOTE-024
The ongoing KEYNOTE-024 study (NCT02142738) was designed
to establish the efficacy and safety of pembrolizumab compared
with standard of care (platinum-based chemotherapies) in patients
with treatment-naive, stage IV NSCLC whose tumors express PD-L1
on at least 50% of tumor cells. Patients were randomly assigned to
receive either a 200-mg fixed-dose of pembrolizumab every 3
weeks or the investigator’s choice of platinum-based combination
chemotherapy. The primary endpoint was PFS, and secondary end-
points were ORR, OS, and safety [50]. Median PFS was 10.3 months
(95% CI 6.7–not reached) versus 6.0 months (95% CI 4.2–6.2) for
pembrolizumab compared with chemotherapy, respectively (HR
0.50; 95% CI 0.37–0.68; P < .001). The estimated 6-month OS rate
was 80.2% in the pembrolizumab arm and 72.4% in the chemother-
apy arm (HR 0.60; 95% CI 0.41–0.89; P = .005). ORR was 44.8% pem-
brolizumab arm and 27.8% in the chemotherapy arm. TRAEs
occurred in 73.4% and 90.0% of patients in the pembrolizumab
and chemotherapy arms, respectively [51]. These findings resulted
in an independent data monitoring committee recommendation
that the chemotherapy arm of the trial be discontinued and all
patients in the trial receiving chemotherapy be offered the option
to receive pembrolizumab [52]. Based on these results, the FDA,
EMA, and Japanese PMDA approved pembrolizumab for first-line
treatment of patients with metastatic NSCLC and high PD-L1
expression (TPS  50%) [40,41,45].
KEYNOTE-021
KEYNOTE-021 (NCT02039674) is an ongoing, multicohort,
phase I/II study to assess the safety and antitumor activity offirst-line pembrolizumab in combination with chemotherapy or
immunotherapy in unresectable or metastatic NSCLC [53]. An anal-
ysis of the randomized phase II pemetrexed/carboplatin cohort
(cohort G) found an improved response rate with pembrolizumab
200 mg intravenously + pemetrexed and carboplatin compared
with pemetrexed + carboplatin alone (ORR 55% versus 29%; P =
.0016). TRAEs of any grade occurred in 93% of pembrolizumab + p
emetrexed and carboplatin patients and in 90% of pemetrexed + c
arboplatin patients, including 39% and 26%, respectively, at grade
 3 [53]. These data were submitted to the FDA in January 2017,
resulting in the accelerated approval of pembrolizumab plus
chemotherapy (pemetrexed plus carboplatin) for the first-line
treatment of metastatic/advanced non-squamous NSCLC regard-
less of PD-L1 expression and with no EGFR or ALK genomic tumor
aberrations [40].
Other PD-1 pathway inhibitors for advanced NSCLC
In addition to the nivolumab and atezolizumab studies (Table 1),
several other PD-1 pathway inhibitors are currently under devel-
opment as potential immunotherapies for patients with advanced
or metastatic NSCLC. These include the anti–PD-L1 monoclonal
antibodies durvalumab and avelumab; the anti–PD-1 monoclonal
antibody PDR001; and the small-molecule PD-L1, PD-L2, and V-
region IgG-containing suppressor of T-cell activation (VISTA) inhi-
bitor CA-170.
Durvalumab is being explored as a treatment option in an open-
label, phase III trial with or without another immune-checkpoint
anti-CTLA4 inhibitor tremelimumab versus standard-of-care
chemotherapy for treatment-naive, EGFR and ALK wild-type,
locally advanced or metastatic NSCLC patients (MYSTIC trial;
NCT02453282) [54]. This followed results from the phase Ib trial
in patients with locally advanced or metastatic NSCLC who were
immunotherapy naive but could have received other systemic
treatments [55]. In this study, objective response occurred in six
patients (23%) in the durvalumab 10–20 mg/kg every 2 or 4 week
s + tremelimumab 1 mg/kg cohort, and this included both patients
who were PD-L1 negative (n = 4) and PD-L1 positive (n = 2), sug-
gesting that PD-L1 status was not predictive of response to this
combination regimen. Of the 26 patients in this dose cohort, 18
were treated with durvalumab 20 mg/kg every 4 weeks + tremeli
mumab 1 mg/kg, and this dose was recommended for the dose
expansion phase [55]. The ongoing global, phase 3 PACIFIC trial is
investigating the efficacy of durvalumab in patients with stage III
unresectable NSCLC after concurrent chemoradiation and no evi-
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umab monotherapy and durvalumab with tremelimumab are also
being compared with standard-of-care therapy in another open-
label phase III trial of previously treated (two prior chemotherapy
regimens) patients with advanced or metastatic, PD-L1–positive
(monotherapy) and PD-L1–negative (combination therapy) NSCLC
(ARCTIC trial; NCT02352948) [57].
Avelumab yielded promising initial results as first-line
monotherapy for advanced NSCLC in the open-label phase Ib JAVE-
LIN solid tumor trial (NCT01772004). Preliminary findings (data
cutoff, October 23, 2015) of the 75 patients who were followed
up for a minimum of 3 months revealed an ORR of 18.7% (95% CI
10.6–29.3), with 1 complete response, 13 partial responses, and
34 patients with stable disease, for a disease control rate of
64.0% [58]. On the back of these findings, avelumab monotherapy
is currently being compared with docetaxel as first-line therapy
in patients with PD-L1–expressing NSCLC in the phase III JAVELIN
Lung 100 trial (NCT02576574) [59], and as second-line therapy in
the phase III JAVELIN Lung 200 trial (NCT02395172).Role of PD-L1 as a predictive biomarker
Elevated PD-L1 expression is common in NSCLC. There are
recent meta-analyses on the prevalence of PD-L1 expression in
malignant tumors, as well as the predictive impact of PD-L1
expression on response to PD-L1 inhibitor treatment [60,61]. In
one of the meta-analyses, which included 61 studies and 17 types
of malignancy, the overall rate of PD-L1–positive tumors, as
defined by the individual studies included, was found to be 44.5%
(95% CI 37.5–51.6%). Furthermore, 51.7% (95% CI 33.1–70.3) of
patients in 13 included studies on NSCLC were PD-L1 positive
[60]. These observations, coupled with the approval of anti–PD-1
antibodies for the treatment of NSCLC, defined the need to evaluate
the role of PD-L1 as a biomarker for treatment in specific treatment
scenarios. A meta-analysis of seven studies (totaling 914 patients)
showed that patients with PD-L1–positive tumors (tumor cell
staining 1%) had a significantly higher ORR than patients with
PD-L1–negative tumors (odds ratio 2.44; 95% CI 1.61–3.68) [61].
Nivolumab and atezolizumab have been approved for treatment
of patients with metastatic NSCLC after failure of platinum-based
chemotherapy, regardless of PD-L1 expression [37,38], whereas
pembrolizumab was approved specifically for use in patients with
NSCLC tumors that express PD-L1 [40,41].
To date, four immunohistochemical PD-L1 assays have been
approved for use in formalin-fixed NSCLC tissue: 22C3 pharmDx
(Dako North America, Inc., Carpinteria, CA), approved as a compan-
ion diagnostic assay for pembrolizumab [62]; 28–8 pharmDx
(Dako), approved as a complementary diagnostic assay for nivolu-
mab [63]; SP263 (Ventana Medical Systems, a member of the
Roche group, Tucson, AZ), approved as a companion diagnostic
assay for pembrolizumab and as a complementary diagnostic assay
for nivolumab [64]; and VENTANA PD-L1 (SP-142) (Ventana Med-
ical Systems), approved as a complementary diagnostic assay for
atezolizumab [65].
While the development of these assays will help toward eluci-
dating the usefulness of PD-L1 expression as a biomarker of thera-
peutic efficacy for their respective drugs, differences in the
antibodies used and in definitions of PD-L1 positivity between
the assays render between-drug and between-study comparison
extremely difficult. Aims to harmonize definitions and provide
clarity on the analytic performance of PD-L1 assays has initiated
cross-industry collaborations such as the Blueprint Project, a con-
sortium of pharmaceutical companies, diagnostic companies, and
academic institutions such as the International Association for
the Study of Lung Cancer (IASCLC) [66,67]. The lack of validationof any staining on cytological material makes the use of these bio-
marker assays difficult in daily practice, in which up to 40% of
advanced disease diagnosis is made on such tumor samples [68].
The 22C3 pharmDx for use with pembrolizumab uses the 22C3
mouse antihuman PD-L1 antibody clone [62,69]. The level of posi-
tivity with this test is identified using TPS, which is defined as the
percentage of viable tumor cells in a sample with 1% membra-
nous staining (at any intensity) and is described as no (TPS < 1%),
low (TPS 1–49%), and high (TPS  50%) expression [62].
The 28–8 pharmDx assay for use with nivolumab uses a 28–8
rabbit antihuman PD-L1 antibody clone, and positivity is stratified
as 1%, 5%, and 10% PD-L1 membrane staining at any intensity
[63]. The assay was particularly precise and reproducible for stain-
ing at 1% and 5% [70].
The VENTANA PD-L1 SP-142 assay uses the rabbit monoclonal
anti–PD-L1 clone SP-142. Unlike the previous two assays, the VEN-
TANA assay evaluates PD-L1 expression on tumor cells and on
tumor-infiltrating immune cells [65]. PD-L1 status is established
by calculating either the percentage of tumor area occupied by
PD-L1–expressing tumor-infiltrating immune cells (of any inten-
sity; IC%) or the percentage of PD-L1–expressing tumor cells (of
any intensity; % TC). PD-L1 expression was considered high at
the cutoff values of 10% for IC or 50% for TC [65].
The VENTANA PD-L1 SP263 is a rabbit antihuman monoclonal
primary antibody that is directed against the cytoplasmic region
of human PD-L1 and has been designed to enable exploration of
the expression of PD-L1 protein in tumor and immune cells in
formalin-fixed, paraffin-embedded NSCLC and head and neck squa-
mous cell carcinoma tissue [64,71,72]. A clinical cutoff of 25% (of
viable tumor cells with PD-L1 membrane staining of any intensity)
is recommended, which discriminates responders from nonrespon-
ders [72].
PD-L1 expression as a biomarker
The role of PD-L1 expression as a biomarker for anti–PD-1 and
anti–PD-L1 antibody treatment efficacy has been explored for
pembrolizumab, nivolumab, and atezolizumab; the results are
summarized in Table 3. KEYNOTE-001 was the first large clinical
trial to demonstrate a positive correlation between PD-L1 expres-
sion and treatment response in NSCLC patients, and it included
an endpoint to validate the 22C3 pharmDx assay by assessing the
longitudinal outcomes of PFS and OS as related to PD-L1 expression
[31,73,74]. The KEYNOTE-010 trial confirmed the findings of the
KEYNOTE-001 trial, validating the use of PD-L1 expression as a
diagnostic factor in combination with pembrolizumab. In that
study, patients with TPS  50% consistently displayed a survival
benefit with pembrolizumab at both tested doses compared with
the docetaxel group and the total population [49], although a post
hoc analysis of efficacy found that pembrolizumab also prolonged
survival over docetaxel in the subset of patients in KEYNOTE-010
with TPS 1–49% (Table 3) [75].
A similar relationship between PD-L1 expression and efficacy
was seen in the phase II POPLAR study (NCT01903993) of ate-
zolizumab versus docetaxel (Table 3) [35]. PD-L1 expression was
prospectively assessed using the VENTANA SP-142 PD-L1 immuno-
histochemistry assay. Increase in improvement in OS was associ-
ated with an increase in PD-L1 expression [35].
The relationship between PD-L1 expression and efficacy of nivo-
lumab in nonsquamous NSCLC was explored in the CheckMate057
trial (NCT01673867), using a retrospective analysis of prospec-
tively collected pretreatment samples and the validated 28–8
pharmDx PD-L1 assay, and was stratified according to level of
membranous PD-L1 staining (1%, 5%, or 10%) [76]. PD-L1
expression and clinical treatment response were strongly associ-
ated in a predictive context at all levels of PD-L1–positive staining
Table 3
Survival and response data for pembrolizumab, nivolumab, and atezolizumab stratified according to PD-L1 expression, measured using three different PD-L1 assays and with
different definitions of PD-L1 expression.
Author Assay PD-L1 inhibitor/comparator n (%) PD-L1 cutoff for
positivity
OS, months
median (95% CI)
PFS, months
median (95% CI)
ORR% (95% CI)
Garon [31] 22C3 pharmDx Pembrolizumab 495 (100) – 12 (9.3–14.7) 3.7 (2.9–4.1) 19.4 (16.0–23.2)
73 (23.3)a TPS  50% NR (NR–NR) 6.4 (4.2–NR) 45.2 (33.5–57.3)
103 (32.9)a TPS 1–49% 10.6 (7.3–NR) 4.1 (2.3–4.4) 16.5 (9.9–25.1)
28 (8.9)a TPS < 1% 10.4 (5.8–NR) 4.0 (2.1–6.2) 10.7 (2.3–28.2)
Herbst [49]
Garon [75]
22C3 pharmDx Pembrolizumab 2 mg/kg 344 (100) — 10.4 (9.4–11.9) 3.9 (3.1–4.1) 18 (14.1–22.5)
139 (40.4)b TPS  50% 14.9 (10.4–NR) 5.0 (4.0–6.5) 30 (22.7–38.8)
205 (59.6)b TPS 1–49% 9.4 (8.7–10.5) 3.1 (2.1–3.8) 10 (6–15)
Pembrolizumab 10 mg/kg 346 (100) — 12.7 (10.0–17.3) 4.0 (2.7–4.3) 18 (14.5–23.0)
151 (43.6)c TPS  50% 17.3 (11.8–NR) 5.2 (4.1–8.1) 29 (22.0–37.1)
195 (56.4)c TPS 1–49% 10.8 (8.9–13.3) 2.3 (2.1–4.0) 10 (6–15)
Docetaxel 343 (100) — 8.5 (7.5–9.8) 4.0 (3.1–4.2) 9 (6.5–12.9)
152 (44.3)d TPS  50% 8.2 (6.4–10.7) 4.1 (3.6–4.3) 8 (4.1–13.4)
191 (55.7)d TPS 1–49% 8.6 (7.8–9.9) 3.9 (2.5–4.3) 10 (6 –16)
Borghaei [76] 28–8 pharmDx Nivolumab 292 (100) — 12.2 (9.7–15.0) 2.3 (2.2–3.3) 19 (15–24)
123 (53.2)e 1% 17.7 4.2 31 (23–40)
95 (41.1)e 5% 19.4 5.0 36 (26–46)
86 (37.2)e 10% 19.9 5.0 37 (27–48)
Docetaxel 290 (100) — 9.4 (8.1–10.7) 4.2 (3.5–4.9) 12 (9–17)
123 (54.9)f 1% 9.0 4.5 12 (7–19)
86 (38.4)f 5% 8.1 3.8 13 (7–22)
79 (35.3)f 10% 8.0 3.7 13 (6–22)
Fehrenbacher[35] VENTANA SP-142 Atezolizumab 144 (100) – 12.6 (9.7–16.4) 2.7 (2.0–4.1) 17 (11.0–23.8)
24 (16.7) TC3 or IC3 15.5 (9.8–NE) 7.8 (2.7–12.3) 37.5
50 (34.7) TC2/3 or IC2/3 15.1 (8.4–NE) 3.4 (1.4–6.9) 22.0
93 (64.6) TC1/2/3 or IC1/2/3 15.5 (11.0–NE) 2.8 (2.6–5.5) 18.3
51 (35.4) TC0 and IC0 9.7 (6.7–12.0) 1.7 (1.4–4.2) 7.8
Docetaxel 143 (100) – 9.7 (8.6–12.0) 3.0 (2.8–4.1) 15 (9.3–21.4)
23 (16.1) TC3 or IC3 11.1 (6.7–14.4) 3.9 (1.9–5.7) 13.0
55 (38.5) TC2/3 or IC2/3 7.4 (6.0–12.5) 2.8 (1.9–3.9) 14.5
102 (71.3) TC1/2/3 or IC1/2/3 9.2 (7.3–12.8) 3.0 (2.8–4.1) 16.7
41 (28.7) TC0 and IC0 9.7 (8.6–12.0) 4.1 (2.7–5.6) 9.8
Abbreviations: CI = confidence interval; NE = not estimable; NR = not reached; ORR = objective response rate; OS = overall survival; PD-L1 = programmed death ligand 1; PFS
= progression-free survival; TC0, TC1, TC2, and TC3 = <1%, 1%; and <5%, 5%, and <50%; and 50% PD-L1–expressing tumor cells, respectively; IC0, IC1, IC2, and IC3 = <1%;
1% and <5%; 5% and <50%; and 50% PD-L1–expressing tumor-infiltrating immune cells, respectively.
a N = 313 evaluable.
b N = 344 evaluable.
c N = 346 evaluable.
d N = 343 evaluable.
e N = 231 evaluable.
f N = 224 evaluable.
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must be interpreted with caution because of the retrospective nat-
ure of this analysis and the fact that tissue from only 78% of the
study population was used for analysis [76].
In contrast with the immunotherapy agents, there seems to be
no association between PD-L1 expression and prognosis in patients
receiving platinum-based chemotherapy. A retrospective study of
patients treated at a single center in Aarhus, Denmark from 2007
to 2012 included 204 treatment-naive patients with stage IIIa, IIIb,
or IV NSCLC who were treated with platinum-based chemotherapy
[77]. No significant association was seen between PD-L1 expres-
sion and survival (log-rank test P = .33). The HR for patients with
PD-L1 TPS 1–49% and 50% was 1.36 (95% CI 0.90–2.06) and 1.09
(95% CI 0.76–1.58), respectively, compared with the patients with
TPS <1% [77]. These findings support the potential specificity of
PD-L1 as a biomarker in conjunction with PD-1 pathway inhibitor
therapies.Challenges with the use of PD-L1 as a predictive biomarker
There remain several challenges regarding the use of PD-L1
assays [78], and further research is necessary to help understand
the utility of PD-L1 as a predictive marker. In addition, the relative
activity of anti–PD-1 or anti–PD-L1 checkpoint blockade in clinical
studies will depend on the activity of the comparator chemother-apy. In that regard, docetaxel is a toxic and poorly active standard
as second-line therapy, allowing the positioning of some anti–PD-1
or anti–PD-L1 compounds as standards of care regardless of PD-L1
expression. In support of this, OS of atezolizumab and nivolumab
in squamous cell carcinoma was superior to that of docetaxel in
the subgroup of PD-L1–negative patients [79,80]. Nivolumab was
equivalent in the nonsquamous subtype in this scenario [76].
Although the PD-L1–negative groups still show either noninferior-
ity or some benefit of standard of care, the PD-L1 biomarker is
associated with a better HR for benefit with increasing expression
level. However, the comparison of anti–PD-1/PD-L1 compounds
and frontline platinum-based chemotherapy requires PD-L1–
related patient selection, as clearly shown through the positive
KEYNOTE-024 trial (which required a PD-L1 tumor proportion
score of 50%) [50] and negative CheckMate 26 trial (which
required the lower cutoff of 5% PD-L1 tumor expression) [81].
There is currently no consensus on a threshold defining PD-L1
positivity, and multiple definitions are used, which hampers com-
parison of agents across studies. Trials thus far have selected
thresholds most commonly at 1%, 5%, 25%, and/or 50%. Analysis
of previous and current trials to determine which thresholds pro-
vided the greatest differences in response rates might provide a
good indication of the most appropriate threshold for future use
in diagnosis and treatment [48,78]. Efforts to see whether several
thresholds can be measured using several assays have begun with
the initiation of cross-industry collaborations such as the Blueprint
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lished that the higher the level of tumor PD-L1 expression, the
more likely it will be that the patient will benefit from treatment
with pembrolizumab [48,78].
The apparent significant, but not unequivocal, relationship
between PD-L1 expression and responsiveness to PD-1/PD-L1
blockade [82] should be accepted with some caution because of
the finding that some patients respond despite low PD-L1 expres-
sion [83] and the lack of a standardized method for evaluating that
expression [82]. It has been suggested that the prediction of
response to anti–PD-L1 treatment could be refined and maximized
by the simultaneous evaluation of multiple relevant biomarkers
[82].
The cell types used to determine PD-L1 positivity are not consis-
tent among studies (e.g. tumor cells [84], tumor-infiltrating
immune cells [31], stromal cells, and combinations thereof [85]),
and the limited number of studies on PD-L1 expression in different
cell types renders direct comparisons between studies challenging
and potentially unreliable [78]. More extensive investigations into
PD-L1 expression in various cell types and the corresponding
observed response rates are warranted to determine the best stan-
dard, with the caveat that differences in tumor biology may result
in different patterns of expression and associated response rates
[48,78].
Another issue is the use of archival versus fresh tissue for PD-L1
expression, which varies between studies; the optimal tissue sta-
tus in this context is a matter of debate. Some studies have argued
that fresh (immediate, pretreatment) samples may not be obtain-
able, necessitating the use of archival (taken before first-line ther-
apy) tissue. Because PD-L1 expression may change in response to
systemic therapies, the use of new, recent samples before PD-L1
inhibitor administration might be more appropriate [78]. In con-
trast, an analysis of samples from the KEYNOTE-010 study revealed
no difference in the PD-L1 expresssion predictive ability between
archival and fresh test tissue [86].
The expression of PD-L1 may vary widely throughout the tumor
so that the PD-L1 status of the biopsy sample might not accurately
reflect the overall immunological status of the tumor [82]. In one
study of 160 patients with operable NSCLC, PD-L1 expression in
tumor cells was assessed in surgically resected and matched
biopsy specimens, revealing a poor correlation between the two
[87]. It was concluded that it would be advisable to take multiple
biopsy samples from different areas of the tumor to enhance the
validity of the results of immunohistochemical evaluations of PD-
L1 [87], although putting this into practice would be difficult if
not impossible for many patients, and there are no standards to
determine this practice. However, in all studies showing an associ-
ation between PD-L1 expression and benefit from therapy, the
relationship between high PD-L1 expression and better outcome
is largely maintained despite the potentially confounding effect
of PD-L1 expression heterogeneity to which all of the samples
would be subjected. The sometimes-conflicting findings regarding
PD-L1 expression and its relationship with response rates warrant
further investigation and refinement of the currently approved
assays [77,78]. Validation of the PD-L1 assays in cytological mate-
rial is ongoing and practically needed.Other potential prognostic markers/biomarkers for
pembrolizumab
Several other potential candidate biomarkers of response to
pembrolizumab are either currently or planned subjects of investi-
gation. CD8+ T-cell concentration and tumor mutational burden
(including increased DNA repair pathway gene mutations), have
been reported as possible predictive biomarkers in NSCLC inresponse to pembrolizumab [48,88,89]. High expression of T-
effector cell and interferon-c–associated genes was associated
with improved survival with atezolizumab in the phase II POPLAR
study, and these gene signatures were not prognostic of survival in
the docetaxel arm, suggesting their potential use as predictive
biomarkers for atezolizumab benefit in NSCLC [35].
Other potential factors that have emerged in recent studies
include smoking – which might be a surrogate of mutation burden
– as well as specific tumor neoantigens, and these require further
research to assess the validity of their use as prognostic factors
in response to pembrolizumab therapy in NSCLC patients
[36,78,88]. Several of these factors may emerge as possible
biomarkers, most likely in combination with PD-L1 immunohisto-
chemistry, but it remains to be seen whether such approaches are
any better than the current standard. In the development of any
biomarker, it is important to consider the practicalities of imple-
mentation on a routine basis.Conclusions
The development of PD-L1 inhibitors for the treatment of
patients with advanced NSCLC provides superior survival benefits
in comparison with the more traditional treatments previously
used. The anti–PD-1 inhibitor pembrolizumab is unique among
the current immunotherapies because it has shown efficacy as a
monotherapy when used as either second-line (PD-L1 expressing)
or first-line (high PD-L1 expressing) therapy for patients with
advanced NSCLC. In addition, initial results from randomized phase
II cohort G of KEYNOTE-021 suggests that pembrolizumab com-
bined with platinum doublet chemotherapy for first-line treatment
in patients with NSCLC is tolerable and effective [53]. Multiple
phase III studies are ongoing to fully evaluate the efficacy of pem-
brolizumab as first-line treatment; pembrolizumab as monother-
apy in patients with NSCLC tumors that express PD-L1 is being
evaluated in KEYNOTE-042 (NCT02220894). The combination of
pembrolizumab with chemotherapy as first-line treatment in
patients with NSCLC is being explored in two phase III studies:
KEYNOTE-189 (NCT02578680) and KEYNOTE-407 (NCT02775435).
Biomarker selection of patients for anti–PD-1 and PD-L1 ther-
apy has proven efficacy and clinical utility. PD-L1 immunohisto-
chemistry is not a perfect biomarker, but no such single
biomarker is known or likely, given the complexity of the immune
response and its regulation. It remains to be seen whether addition
biomarkers accounting for tumor mutational burden (or a surro-
gate) and some assessment of tumor inflammation will enhance
the accuracy of patient selection.Role of the funding source
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